Clinical Trials Logo

Clinical Trial Summary

The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).


Clinical Trial Description

The VONTAPE trial will compare two treatment regimens for Helicobacter pylori eradication among adolescent patients presented to the gastroenterology department in an Egyptian institute. the eligible subjects will be randomly assigned to one of the two protocols (vonoprazan based vs. proton pump inhibitor-based triple therapy) for two weeks. then the eradication rates will be compared between the two study groups to see if there is a difference in efficacy. The currently available eradication regimens in our country show a low to intermediate eradication rate (50-75%). At the same time, H. pylori infection is prevalent. Recently, the FDA approved vonoprazan-based regimens for adult H. pylori infection with high eradication rates even in the settings of clarithromycin antibiotic resistance. In the VOTSAPE trial, we will test this efficacy in the < 18 years adolescents. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06162949
Study type Interventional
Source Alexandria University
Contact Sameh A Lashen, MD
Phone 1274117543
Email sameh.lashen@alexmed.edu.eg
Status Recruiting
Phase Phase 3
Start date January 1, 2024
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03567681 - Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression Phase 4
Recruiting NCT05793749 - Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy N/A